View
217
Download
0
Category
Preview:
Citation preview
8/3/2019 Vicki Brower- Is Nanotechnology Ready for Primetime?
http://slidepdf.com/reader/full/vicki-brower-is-nanotechnology-ready-for-primetime 1/3
N E W S
Journal of the National Cancer Institute, Vol. 98, No. 1, January 4, 2006 NEWS 9
In October, the National Cancer Insti-
tute made its first nanotechnology re-
search awards worth $33.3 million to
12 research groups and seven hubs.
A month later, at the Molecular Targetsand Cancer Therapeutics meeting in
Philadelphia, a press conference devoted
exclusively to nanotechnology high-
lighted several experimental studies
using nanoparticles, including a
liposome – nanoparticle gene therapy
designed to home in on and kill cancer
cells wherever they are throughout the
body. Nanotechnology’s potential appli-
cation to cancer seems to be in the news
almost weekly, with new uses of the
technology for diagnosis and treatment
moving rapidly from the lab toward clin-ical trials. But along with several prom-
ising discoveries have come unanswered
questions about nanotechnology’s safety
for human health and the environment.
Since the discovery of carbon nano-
tubes and their unusual properties in
1991, the hope for and hype of nano-
technology’s potential to better diagnose
and treat cancer have blossomed. In
September 2004, the NCI initiated a
comprehensive 5-year, $144.3 million
research effort, the Alliance for Nano-
technology in Cancer, to develop and
translate cancer-related nanotechnology
research into clinical practice. Its first
awards were $7 million to the Cancer
Nanotechnology Platform Partnerships
and $26.3 million to seven Centers of
Cancer Nanotechnology Excellence, and
they span a wide range of technologies
and cancer types. Projects funded in-
clude developing applications to treat
multidrug-resistant tumors, early cancer
detection using nanoprobes targeted to
angiogenic signatures, DNA-linked den-drimer nanoparticles for diagnosis and
treatment, near-infrared fluorescence
nanoparticles for optical imaging, and
hybrid nanotechnology particles for im-
aging and treatment of prostate cancer.
Nanotechnology deals with structures
that range from 1 to 100 nm — about the
size of a virus — and derives its name
from the Greek word for “dwarf.” (A
nanometer is a billionth of a meter, or
Is Nanotechnology Ready for Primetime?about 25 millionths of an inch). “ Nano-
technology allows us to make materials
that are thousands of times smaller than
the smallest cell in the body,” said James
R. Baker Jr., M.D., professor of biologicnanotechnology at the University of
Michigan in Ann Arbor. “Because these
materials are so small, they can easily get
inside cells and change how they work.”
Baker is developing nanosized den-
drimers, molecules with treelike
branches that can be attached to drugs.
Such nanosized “Trojan horses” are de-
signed to smuggle anticancer drugs into
cells and are expected to increase the
drug’s killing capacity and reduce toxic
side effects, Baker said. There are about
700 products now on the market that usenanotechnology, from sunscreens to elec-
tronics to the first cancer drug, Abraxane
(albumin-bound nanosized particles of
paclitaxel), which was approved last
January in the United States for second-
line treatment of metastatic breast cancer.
With the National Science Founda-
tion’s prediction that the market for nan-
otech products and services will hit $1
trillion by 2015, and the U.S. government
already investing $1 billion a year in the
technology, nanotechnology is becoming
big business. “It’s the beginning of a tidal
wave of products,” said David Rejeski,
director of the Project on Emerging Nano-
technologies at the Woodrow WilsonInternational Center for Scholars.
In November, drug delivery pioneer
Robert Langer, Ph.D., of the Massa-
chusetts Institute of Technology in
Cambridge, Mass.; Omid Farokhzad,
M.D., of Brigham and Women’s Hospital
in Boston; and colleagues presented re-
search at the 13th European Cancer Con-
ference in Paris that showed for the first
time that targeted delivery to the prostate
was possible using nanoparticle – nucleic
acid ligand conjugates. They synthesized
nanoparticles for controlled drug releaseusing a polymer with a long circulating
half-life to encapsulate docetaxel. They
used stable RNA molecules on the
particle surface to bind to the prostate-
specific membrane antigen (PSMA) and
guide the particles to the cancer to de-
liver the chemotherapy to the cells. “We
anticipate filing an [investigational new
drug application] for clinical trials within
18 months,” Farokhzad said.
While researchers believe that nan-
otechnology can improve drug delivery
and imaging, concerns are growing and
evidence is accumulating that with the
new technology will come unforeseen
human and environmental health haz-
ards. Some nanotechnology advocates
warn that more human and environmen-
tal safety testing must be conducted on
products before they are approved.
“We wholeheartedly agree with
safety concerns,” said Farokhzad. His
team is developing their targeted nano-
particles specifically to bypass the
spleen and liver; their tests have shownthat the nontargeted nanoparticles stick
in the microvasculature of the liver and
spleen, which is undesirable. The final
product, which will be given intrave-
nously, must home in only to the pros-
tate and nowhere else, he added.
One recent study conducted by
the International Life Sciences Insti-
tute’s Nanomaterial Toxicity Screening
Working Group, coauthored by
This nanosized dendrimer—with folate and a
fluorescent protein on either end—selectively
targets cancer cells and docks with folate
receptors on the cell surface. It is one of the
many possible ways in which nanotechnology
may someday be applied in cancer.
Photo courtesy of James R. Baker Jr. (design by Paul D. Trombley)
8/3/2019 Vicki Brower- Is Nanotechnology Ready for Primetime?
http://slidepdf.com/reader/full/vicki-brower-is-nanotechnology-ready-for-primetime 2/3
10 NEWS Journal of the National Cancer Institute, Vol. 98, No. 1, January 4, 2006
N E W S
routes and affect other parts of the
body, including the heart, liver, kidneys,
and brain. “ Next to nothing is known
about the impact of engineered nanoma-
terials on these organs … or if ingested
as a food additive or by accident”
said Rejeski. In short, there are more
questions than answers for this technol-ogy that is developing faster than policy,
he added.
Rejeski urged that a cooperative in-
ternational effort be made to develop
priorities, align researchers to address
them, and implement an information
infrastructure to support global collabo-
ration. He also strongly recommended
that a blueprint be developed for future
research, oversight, public education
about nanotech, and emergency plans
related to accidental release of nano-
materials into the environment to
avoid pitfalls of public perception
similar to those seen with genetically
engineered organisms.
It’s also unclear how exactly nanote-
chnology products will be regulated in
the future. The U.S. Food and Drug
Administration
has noted that
it does not reg-
ulate technolo-
gies and
maintains in astatement on
its Web site
that “The proc-
ess of approval
for nanomate-
rials will be the
same as that
used for other products making the same
claims.” Although the agency is partici-
pating in several nanotech working
groups, including one to identify regula-
tory challenges, it says that the existing
preclinical tests are adequate; “As newtoxicological risks that derive from
nanomaterials are identified, new tests
will be required.” It does note that new
testing models might be needed and
acknowledges that limited basic public-
health research exists on nanomaterials
and that industry and academia must
plan and conduct research to identify
potential risks and to develop adequate
methods to characterize nanomaterials.
Earlier reports and studies also raised
questions about safety. In July 2004, the
United Kingdom’s Royal Society and
Royal Academy of Engineering released
a study detailing gaps in knowledge of
nanotechnol-
ogy’s impact on
health and theenvironment.
A July 2004
study published
in Environmen-
tal Health
Perspectives
showed that
buckminster-
fullerenes, or
buckyballs —
one of the most popular nanomaterials —
can have adverse effects on marine
organisms: Oxidative stress was found in
the brains and gills of young largemouth
bass exposed for 48 hours to water con-
taining fullerenes at a concentration
likely to be found in an aquatic environ-
ment. However, in October, scientists at
Rice University’s Center for Biological
and Environmental Nanotechnology in
Houston found that water-soluble carbon
nanotubes they are developing are less
toxic to cells than the traditional hollow,
insoluble carbon ones. When nanotubes
and buckyballs were made nontoxic withminor chemical modifications, cytotoxic-
ity of the new nanotubes occurred at 200
parts per billion, compared with 20 parts
per billion.
The House of Representatives’
Committee on Science held its first
hearing on the environmental and safety
impact on nanotechnology in November,
and the general consensus was that more
strategic research is needed to determine
whether the technology is safe and prop-
erly regulated, said Maynard. Rejeski
noted that “there are currently no studieson exposure and response to engineered
nanomaterials in humans. Nevertheless,
our experience with ultrafine aerosol
particles (smaller than 100 nm) has
shown that inhalation of micro- and na-
nosized fi bers and particles can lead to
increased rates of cancer, lung disease,
and adverse respiratory symptoms.”
Nanometer-diameter particles could
leave the lungs via unconventional
David Rejeski
Omid Farokhzad
Andrew Maynard, Ph.D., chief science
advisor for the Project on Emerging
Nanotechnologies, raised several red
flags based on previous health and
safety research and on what is known
about the safety of nanosized particu-
late matter. Animal studies show that
inhaled or implanted fine particulatematter can cause an increase in lung
inflammation, oxidative stress, and dis-
tant organ involvement and lead to in-
creased cell death and inflammatory
cytokine production.
One of the hallmarks of particles is
that their behavior in the nanorange dif-
fers from that when they are larger. For
example, nanosized particles of gold and
carbon may be toxic at the nanoscale,
whereas larger particles of the same ma-
terials may not be. Other nanomaterials
being used in research include carbon-
based particles called fullerenes, metal
oxide particles, polymer nanoparticles,
and quantum dots. Biological activity of
particles increases as particle size de-
creases, the ILSI study notes. “There is a
strong likelihood that biological activity
of nanoparticles will depend on physi-
ochemical parameters not routinely con-
sidered in toxicity screening studies,”
the study authors wrote. For this reason,
it recommends that physiochemical, in
vitro, and in vivo testing be done on allnanomaterials before they are used in
drugs and devices.
Few existing nanotoxicology studies
address the effects of nanomaterials in a
variety of organisms and environments,
but what does exist raises concerns
about their safety and toxicity, Maynard
observed. Overall number and surface
area are also important to consider in
addition to size. Exposure through inha-
lation, skin uptake, ingestion, and injec-
tion must be tested, the report concludes.
Coating quantum dots may render themsafer, but more research is need to deter-
mine long-term stability of the coatings
in the body and when released into the
environment. Nanoparticles can also
cross the blood – brain barrier, which may
be risky. Methods used to test have var-
ied, leading to different results, which
makes it important to standardize test-
ing; the report suggests ways to stand-
ardize screening of nanomaterials.
8/3/2019 Vicki Brower- Is Nanotechnology Ready for Primetime?
http://slidepdf.com/reader/full/vicki-brower-is-nanotechnology-ready-for-primetime 3/3
N E W S
Journal of the National Cancer Institute, Vol. 98, No. 1, January 4, 2006 NEWS 11
The Wilson Center will be releasing
another report in January 2006 that
analyzes U.S. regulatory options
for nanotechnology.
The Environmental Defense Fund
calls nanotechnology a “double-edged
sword” that must be managed closely by
government – industry partnership. The first
inventory of government-funded, health,
safety, and environmental risk – related
research was released on November 29 by
the Wilson Center’s Project on Emerging
Nanotechnologies. Its goal: to help define
where research gaps exist and developing
a roadmap for future risk-related research.
“The government is in a good position to
fund generic research, and industry can
support specific research,” said Maynard.
“Let’s fill in the gaps.”
—Vicki Brower© Oxford University Press 2006. DOI: 10.1093/jnci/djj028
Recommended